Results by group107

Each measurement the trial posted, group by group, in the words and numbers it posted.

21 to 40 of 107

Outcome	Group	Category	Value	Spread	Units
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 07: Vandetanib concentration centre of tumour	4570		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 07: Vandetanib concentration middle of tumour	531		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 07: Vandetanib concentration edge of tumour	441		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 07: Vandetanib concentration 1cm away from tumour	2760		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08: Vandetanib concentration centre of tumour	1140		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (1cm lesion): whole tumour Vandetanib concentration	93500		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (inferior lesion): Vandetanib concentration centre of tumour	6180		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08: Vandetanib concentration middle of tumour	1240		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (inferior lesion): Vandetanib concentration middle of tumour	1440		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08: Vandetanib concentration edge of tumour	2840		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (inferior lesion): Vandetanib concentration edge of tumour	2710		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08: Vandetanib concentration 1cm away from tumour	29100		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (1 cm lesion): Vandetanib concentration 1cm away from tumour	5350		ng/mL
Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 08 (inferior lesion): Vandetanib concentration 1cm away from tumour	6010		ng/mL
Time Taken to Reach the Maximum Concentration (Tmax) of Vandetanib and N-desmethyl Vandetanib in Plasma Following Treatment With BTG-002814	BTG-002814	Vandetanib Plasma Tmax	26.0	Standard Deviation 67.08	hours
Time Taken to Reach the Maximum Concentration (Tmax) of Vandetanib and N-desmethyl Vandetanib in Plasma Following Treatment With BTG-002814	BTG-002814	N-desmethyl Plasma Tmax	0.8	Standard Deviation 1.04	hours
Concentration of Vandetanib and N-desmethyl Vandetanib in Plasma Over Time Until End of Study Following Treatment With BTG-002814	BTG-002814	Vandetanib Plasma AUCEoS	6979.3	Standard Deviation 3188.21	ng*h/mL
Concentration of Vandetanib and N-desmethyl Vandetanib in Plasma Over Time Until End of Study Following Treatment With BTG-002814	BTG-002814	N-desmethyl Plasma AUCEoS	81.1	Standard Deviation 169.40	ng*h/mL
Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 01: N-desmethyl Vandetanib concentration centre of tumour	4620		ng/mL
Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814	BTG-002814	Subject 01: N-desmethyl Vandetanib concentration middle of tumour	4740		ng/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03291379/results?page=2

API reference For AI assistants